Cutaneous Immunofluorescence Antibodies, IgG and IgG4, Serum
Use
This test is useful for confirming the presence of IgG and/or IgG4 antibodies to diagnose pemphigoid, pemphigus, epidermolysis bullosa acquisita, or bullous lupus erythematosus. These conditions are associated with autoimmune blistering disorders where patients produce IgG and/or IgG4 anti-basement membrane zone (BMZ) antibodies. The detection of these antibodies aids in the diagnosis of such disorders. The sensitivity of detection is increased by testing serum using sodium chloride-split primate skin and primate esophagus as substrates with both IgG and IgG4 reactants.
Special Instructions
Not provided.
Limitations
Results should be interpreted alongside clinical information, histopathologic, direct immunofluorescence studies, and histopathologic patterns. Low titer antibodies should not be used alone for diagnosis without such support. The test is performed using indirect immunofluorescence assays.
New York Approved
Methodology
Immunoassay (Indirect Immunofluorescence Assay (IFA))
Biomarkers
IgG
ProteinIgG4
Protein
LOINC Codes
- 93233-5 - ICS IgG Ser Ql IF
- 29994-1 - BM IgG Ser Ql IF
- 104832-1 - Skin IgG Ser Ql Human split skin sub
- 48767-8 - Annotation comment Imp
Result Turnaround Time
2-7 days
Related Documents
For more information, please review the documents below
Specimen
Serum
Volume
2 mL
Minimum Volume
0.5 mL
Container
Serum gel (preferred), Red top (acceptable), Plastic vial
Collection Instructions
Centrifuge and aliquot serum into a plastic vial.
Stability Requirements
| Temperature | Period |
|---|---|
| Room Temperature | 14 days |
| Refrigerated | 14 days |
| Frozen | 30 days |